Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213078 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL172658 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL132806 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5216014 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5220519 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL132805 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL1931445 | 0.86 | ESR2 (0.43) | NPC1ALDH1A1RAB9A | |
| SCHEMBL5426977 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5426986 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5426982 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1265890-B1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-20040058893-A1 | Antiviral nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2004-03-25 | — | — | US | disclosed |
| EP-1140937-B1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2003-11-12 | — | — | EP | disclosed |
| US-6566365-B1 | Administering a therapeutically effective amount of nucleoside analog compound for therapy of Flaviviridea viral infection in a host | BIOCHEM PHARMA INC. (CA) | 2003-05-20 | — | — | US | disclosed |
| US-6545001-B2 | Antiviral nucleoside analogues | BIOCHEM PHARMA, INC. (CA) | 2003-04-08 | — | — | US | disclosed |
| EP-1225899-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTION USING NUCLEOSIDE ANALOGUES | Virochem Pharma Inc. (CA) | 2002-07-31 | — | — | EP | disclosed |
| US-6358963-B1 | FOR THERAPY OF VIRAL INFECTIONS | BIOCHEM PHARMA INC. (CA) | 2002-03-19 | — | — | US | disclosed |
| US-20010049372-A1 | Antiviral nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2001-12-06 | — | — | US | disclosed |
| EP-1140937-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001032153-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTION USING NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000039143-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049372-A1 | Antiviral nucleoside analogues | TYMP, SAMHD1, SLC29A1 | CHRNB2 4825/4885CHRNA5 4393/4885CHRNA7 4225/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | CHRNB2 3114/4885CHRNA5 1375/4885CHRNA7 2699/4885 |
| US-20040058893-A1 | Antiviral nucleoside analogues | TYMP, SAMHD1, SLC29A1 | CHRNB2 4825/4885CHRNA5 4393/4885CHRNA7 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.